Recombinant Erythropoietin Is Neuroprotective in a Novel Mouse Oxidative Injury Model
Authors:
- Sandra E. JuulSJSandra E. Juul
- Ronald J. McPhersonRMRonald J. McPherson
- Theodor K. BammlerTBTheodor K. Bammler
- Jasmine WilkersonJWJasmine Wilkerson
- Richard P. BeyerRBRichard P. Beyer
- Federico M. FarinFFFederico M. Farin
- 25 October 2007
- journal article
- Published by S. Karger AG in Developmental Neuroscience
- Vol. 30 (4) , 231-242
Abstract
To identify neuroprotective changes in gene expression, we developed a neonatal mouse model of moderate to severe oxidative brain injury and hypothesized that recombinant erythropoietin (rEpo) would decrease the expression of proapoptotic and proinflammatory genes 24 and 48 h, respectively, after injury and increase the expression of neurogenic and angiogenic genes 168 h after injury. Postnatal day 10 BALB-c mice underwent sham surgery or right common carotid artery occlusion followed by alternating hypoxia and hyperoxia and were then treated with rEpo (5,000 U/kg s.c.) or saline (vehicle) daily for up to three doses. At death, gross brain injury was assessed, then hippocampus, cortex, and thalamus were isolated for RNA or protein extraction. Microarray analysis, real-time polymerase chain reaction, and Bio-Plex® suspension array system validation were performed. rEpo decreased both incidence and severity of brain injury (median injury score 3 vs. 0, p < 0.0001) and reduced the injury-induced increases in interleukin-1α and interleukin-6 gene expression (p < 0.001), with corresponding effects on protein translation. Similarly, the expression of caspase-1, caspase-4, and caspase-6 and of p53 was increased by brain injury at 24 h, but mitigated by rEpo (p < 0.01). The interleukin-10 expression was higher in the rEpo-treated animals. Apoptotic and proinflammatory gene expression persisted for 168 h. There was no increase in angiogenic gene expression at the time points studied.Keywords
This publication has 12 references indexed in Scilit:
- Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005Public Health Nutrition, 2009
- Interference with TGF-β signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuriaAmerican Journal of Physiology-Renal Physiology, 2007
- The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFβ1 responses in human proximal-tubule epithelial cellsBiochemical Journal, 2005
- Nitric oxide synthase inhibition exaggerates the hypotensive response to ghrelin: role of calcium-activated potassium channelsJournal Of Hypertension, 2005
- Plasma Concentration of Big Endothelin-1 and Its Relation With Plasma NT-proBNP and Ventricular Function in Heart Failure PatientsRevista Española de Cardiología (English Edition), 2005
- Effects of Ghrelin Administration on Left Ventricular Function, Exercise Capacity, and Muscle Wasting in Patients With Chronic Heart FailureCirculation, 2004
- Brain and Other Natriuretic Peptides: Molecular AspectsEuropean Journal of Heart Failure, 2004
- Iodine deficiency disorders in 15 districts of India.Indian Journal of Pediatrics, 2004
- Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brainChild's Nervous System, 2003
- Transcriptional Activators of TGF-β Responses: SmadsCell, 1998